Heweizhixie capsuleTherapy on Patients With Diarrhea
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02607176 |
Recruitment Status :
Completed
First Posted : November 17, 2015
Last Update Posted : July 5, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diarrhea | Drug: Heweizhixie capsule | Phase 4 |
The objective of this study is to evaluate safety and efficacy of Heweizhixie Capsule in patients with diarrhea.This is a Phase 4 Open Label trial, enroll 2400 patients with diarrhea Primary Outcome Measure:Percent of subjects with treatment Success
Secondary Outcome Measures:
Number of unformed stools passed per 24 h period Time (hours) from first intake to the last unformed stools Change from baseline of Leeds dyspepsia questionnaire score Percent of subjects with AE.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 2400 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Post -Marketing Drug Evaluation(Phase IV Clinical Trial) to Study the Safety and Efficacy of Heweizhixie Capsule in Patients With Diarrhea |
Study Start Date : | October 2015 |
Actual Primary Completion Date : | December 2017 |
Actual Study Completion Date : | April 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: Heweizhixie capsule
Heweizhixie capsule, 0.33g/#, 3 #, Tid, Oral
|
Drug: Heweizhixie capsule
3 #, Tid, Oral for 3 days
Other Name: Changdaoqing capsule |
- Percent of subjects with treatment Success [ Time Frame: 3 days ]Percent of subjects with treatment Success
- Number of unformed stools passed per 24 h period [ Time Frame: per 24 h period ]Number of unformed stools passed per 24 h period
- Time (hours) from first intake to the last unformed stools [ Time Frame: 3 days ]Time (hours) from first intake to the last unformed stools
- Change from baseline of leeds dyspepsia questionnaire score [ Time Frame: 3 days ]Change from baseline of leeds dyspepsia questionnaire score
- Percent of subjects with AE [ Time Frame: 3 days ]Percent of subjects with AE

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
3 or more unformed stools in 24 hours Male and female subjects between 18 and 80 years old Signed informed consent
Exclusion Criteria:
Subjects with serum ALT more than 5ULN or serum Cr more than 442umol/L Subjects are pregnant now, likely to become pregnant Subjects, who in the opinion of the Investigator, are not suitable candidates for enrollment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02607176
China | |
Long hua hospital | |
Shanghai, China, 200032 |
Study Chair: | QingShan Zheng, Dr | Shanghai University of Chinese Medicine |
Responsible Party: | Shanghai University of Traditional Chinese Medicine |
ClinicalTrials.gov Identifier: | NCT02607176 |
Other Study ID Numbers: |
ZY3-CCCX-3-1001 |
First Posted: | November 17, 2015 Key Record Dates |
Last Update Posted: | July 5, 2019 |
Last Verified: | April 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Diarrhea Signs and Symptoms, Digestive |